TGF-β – an excellent servant but a bad master

Lenka Kubiczkova, Lenka Sedlarikova, Roman Hajek and Sabina Sevcikova*

Abstract

The transforming growth factor (TGF-β) family of growth factors controls an immense number of cellular responses and figures prominently in development and homeostasis of most human tissues. Work over the past decades has revealed significant insight into the TGF-β signal transduction network, such as activation of serine/threonine receptors through ligand binding, activation of SMAD proteins through phosphorylation, regulation of target genes expression in association with DNA-binding partners and regulation of SMAD activity and degradation. Disruption of the TGF-β pathway has been implicated in many human diseases, including solid and hematopoietic tumors. As a potent inhibitor of cell proliferation, TGF-β acts as a tumor suppressor; however in tumor cells, TGF-β looses anti-proliferative response and become an oncogenic factor. This article reviews current understanding of TGF-β signaling and different mechanisms that lead to its impairment in various solid tumors and hematological malignancies.

Keywords: TGF-β, SMAD proteins, Oncogene, Suppressor, Solid tumors, Leukemia, Multiple myeloma

Introduction

Although our understanding of molecular mechanisms that underlie cancer development and progression has increased, cancer remains a significant health concern in many developed countries. There is a strong requirement for new diagnostic and treatment options as well as elucidation of how cells acquire the six essential phenotypes, or hallmarks, necessary to become fully malignant [1]. Pharmacological targeting of cancer hallmarks may offer new possibilities of effectively treating development and/or metastases of human tumors (reviewed in [2]). Transforming Growth Factor-β (TGF-β) is a key player in cell proliferation, differentiation and apoptosis. The importance of this regulation is apparent from the role of TGF-β in development and consequences of aberrant TGF-β signaling in cancer [3]. Nevertheless, it is still not elucidated how malignant cells overcome the cytostatic functions of TGF-β or how TGF-β stimulates the acquisition of cancer hallmarks of developing and progressing human cancers. In this paper, we review different molecular and cellular mechanisms that lead to impairment of TGF-β signaling in various solid tumors and hematological malignancies.

History of TGF-β discovery

In the early 1980s, it had become apparent that cell growth is controlled by many polypeptides and hormones. A new hypothesis of ‘autocrine secretion’ was postulated, which suggested that polypeptide growth factors are able to cause malignant transformation of cells [4]. A new polypeptide called SGF (Sarcoma Growth Factor) was discovered in cultures of transformed rat kidney fibroblasts [5]; soon it became apparent that this factor is a mixture of at least two substances with different functions. They were called Transforming Growth Factor-α (TGF-α) and Transforming Growth Factor-β (TGF-β) [6]. TGF-β was further described by Roberts and Sporn as a secreted polypeptide capable of inducing fibroblast growth and collagen production [7]. Soon after its discovery, TGF-β was found to inhibit cell proliferation as well; thus, a dual role of this cytokine was recognized [8,9].

TGF-β family and isoforms

The TGF-β superfamily is composed of a large group of proteins, including the activin/inhibin family, bone morphogenetic proteins (BMPs), growth differentiation factors (GDFs), the TGF-β subfamily, and the glial cell line-derived neurotrophic factor (GDNF) family. This review will focus solely on the TGF-β family.
The TGF-β proteins have been discovered in a variety of species, including invertebrates as well as vertebrates. TGF-β superfamily is fundamental in regulation of various biological processes, such as growth, development, tissue homeostasis and regulation of the immune system [10,11].

Beta-type subfamily growth factors are homodimeric or heterodimeric polypeptides with multiple regulatory properties depending on cell type, growth conditions and presence of other polypeptide growth factors. Since their expression is also controlled by distinct promoters, their secretion is temporal and tissue specific [12].

There are three known isoforms of TGF-β (TGF-β1, TGF-β2 and TGF-β3) expressed in mammalian tissues; they contain highly conserved regions but diverge in several amino acid regions. All of them function through the same receptor signaling pathways [13,14].

TGF-β1, the most abundant and ubiquitously expressed isoform, was cloned from human term placenta mRNA [15]. In mouse development, Tgf-β1 mRNA and/or protein have been localized in cartilage, endochondral and membrane bone and skin, suggesting a role in the growth and differentiation of these tissues [16].

TGF-β2 was first described in human glioblastoma cells. It was found that TGF-β2 is capable of suppressing interleukin-2-dependent growth of T lymphocytes. Thereby, it was named glioblastoma-derived T cell suppressor factor (G-TsF). Physiologically, TGF-β2 is expressed by neurons and astroglial cells in embryonic nervous system [17]. It is also important in tumor growth enhancing cell proliferation in an autocrine way and/or reducing immune-surveillance of tumor development [18]. Their mature forms, which consist of the C-terminal 112 amino acids, TGF-β1 and TGF-β2 share 71% sequence similarity [19].

The third isoform, TGF-β3, was isolated from a cDNA library of human rhabdomyosarcoma cell line; it shares 80% of amino acid sequence with TGF-β1 and TGF-β2. Studies on mice demonstrated essential function of Tgf-β3 in normal palate and lung morphogenesis and implicated this cytokine in epithelial-mesenchymal interaction [20,21]. Its mRNA is present in lung adenocarcinoma and kidney carcinoma cell lines; interestingly, umbilical cord expresses very high level of TGF-β3 [19].

**TGF-β synthesis and activation**

Mature dimeric form of TGF-β, composed of two monomers stabilized by hydrophobic interactions and disulfide bridge, initiates intracellular signaling [22]. The three TGF-βs are synthesized as pro-proteins (pro-TGF-βs) with large amino-terminal pro-domains (called latency associated proteins – LAPs), which are required for proper folding and dimerization of carboxy-terminal growth-factor domain (mature peptide) [23]. This complex is called ‘small latent complex’ (SLC). After folding and dimerization, TGF-β dimer is cleaved from its pro-peptides in trans-Golgi apparatus by furin type enzymes; however, it remains associated with its pro-peptide through noncovalent interactions, creating ‘large latent complex’ (LLC). Most cultured cell types release latent TGF-β into extracellular matrix as LLC which in addition includes a 120–240 kDa glycoprotein called latent TGF-β binding protein (LTBP) [24]. LTBP is composed primarily of two kinds of cysteine-rich domains: EGF-like repeats (most of which are calcium-binding) and eight-cysteine domains [25]. LTBP participates in the regulation of latent TGF-β bioavailability by addressing it to the extracellular matrix (ECM) [26]. Non-active TGF-β stays in ECM; its further activation is a critical step in the regulation of its activity (Figure 1).

A number of papers have reported TGF-β activation by retinoic acid and fibroblast growth factor-2 (FGF-2) in endothelial cells [27,28], or by endotoxin and bleomycin in macrophages [29]. Further, a variety of molecules is involved in TGF-β activation. Proteases including plasmin, matrix metaloproteases MMP-2 and MMP-9, are TGF-β activators *in vitro* [30,31]. Other molecules involved in the mechanism of activation are thrombospondin-1 [32], integrins, such as αVβ6 or αVβ8 [33,34], or reactive oxygen species (ROS).

Moreover, latent TGF-β present in conditional medium is activated by acid treatment (pH 4.5) *in vitro* [35]. *In vivo*, a similar pH is generated by osteoclasts during bone resorption. Since the bone matrix deposited by osteoblasts is rich in latent TGF-β, the acidic environment created by osteoclasts *in vitro* might result in latent TGF-β activation [36].

**TGF-β receptors**

In most cells, three types of cell surface proteins mediate TGF-β signaling: TGF-β receptor I (TβRI), II (TβRII) and III (TβRIII) [13,37]. Out of these three receptors, TβRIII, also called betaglycan, is the largest (250–350 kDa) and most abundant binding molecule. This cell-surface chondroitin sulfate / heparan sulfate proteoglycan is expressed on both fetal and adult tissues and most cell types [38]. Endoglin (CD105) was shown to act as type III receptor for TGF-β as well [39]. Endoglin is a membrane, an RGD-containing glycoprotein, which is expressed in a limited set of cell types, primarily vascular endothelial cells, several hematopoietic cell types, bone marrow stromal cells and chondrocytes. Its expression strongly increases in active vascular endothelial cells upon tumor angiogenesis [40-42]. Moreover, in normal brain, it was found to be expressed in the adventitia of arteries and arterioles, and it is expressed on several types of tumor cells, such as invasive breast cancers and cell lines or renal cell carcinoma [43-45]. Although betaglycan and endoglin are co-receptors not directly
involved in intracellular TGF-β signaling due to lack of kinase domain, they can control access of TGF-β to TGF-β receptors and consequently modulate intracellular TGF-β activity [46,47]. Betaglycan binds all three isoforms of TGF-β, with higher affinity for TGF-β2; however, endoglin binds TGF-β1 and -β3 with constant affinity and has only weak affinity for TGF-β2 [39,48].

TβRI and TβRII mediate signal transduction. Both receptors are transmembrane serine/threonine kinases, which associate in a homo- or heteromeric complex and act as tetramers. They are organized sequentially into an N-terminal extracellular ligand-binding domain, a transmembrane region, and a C-terminal serine/threonine kinase domain. The type II receptors range from 85 to 110 kDa, while the type I receptors are smaller and their size ranges from 65 to 70 kDa [49]. Moreover, TβRII contains a characteristic, highly conserved 30 amino acids long GS domain in the cytoplasmic part, which needs to be phosphorylated to fully activate TβRI [36]. TβRII contains 10 bp polyadenine repeat in the coding region of the extracellular domain. This region is frequently a target of changes leading to frameshift missense mutations or early protein terminations that result in truncated or inactive products [50].

TGF-β receptors activation

Bioactive forms of TGF-βs are dimers held together by hydrophobic interactions and, in most cases, by an intersubunit disulfide bond as well. The dimeric structure of these ligands suggests that they function by bringing together pairs of type I and II receptors, forming heterotrameric receptor complexes [51]. Binding of TGF-β to extracellular domains of both receptors also induces proper conformation of the intracellular kinase domains. These receptors are subject to reversible post-translational modifications (phosphorylation, ubiquitylation and

---

Figure 1 TGF-β synthesis and activation. TGF-βs are synthesized as inactive precursors that contain pre-region (Signal peptide) and pro-region (NTerminal peptide – LAP). Processing of inactive form starts with proteolytic cleavage that removes signal peptide from pre-pro-TGF-βs form. After dimerization, TGF-βs are cleaved by proteases (eg. Furin) into C-terminal mature peptides and N-terminal LAP (Latency Associated Peptide). TGF-βs with LAP form small latent complexes (SLP) that are transported to extracellular matrix where can further covalently bind to latent TGF-β binding protein (LTBP) to form a large latent complexes (LLC). LTBP is able to connect inactive TGF-β forms to ECM proteins. This interaction is further supported by covalent transglutaminase-induced (TGase) crosslinks. Activation of TGF-β starts with release of LLC from ECM by proteases. Then, the mature protein is cleaved from LTBP, which is provided in vitro by acidic condition, pH or plasmin or in vivo by thrombospondin (TSP). Once the active TGF-β family member is released from the ECM, it is capable of signaling.
sumoylation) that regulate stability and availability of receptors as well as SMAD and non-SMAD pathway activation.

Receptor phosphorylation activates TGF-β signaling pathway – the ligand binds to TβRII first, followed by subsequent phosphorylation of a Gly-Ser regulatory region (GS-domain) within TβRI. This leads to incorporation of TβRI and formation of a large ligand-receptor complex that consists of dimeric TGF-β ligand and two pairs of TβRI and TβRII [52]. The TGF-β receptor complex is extremely stable upon solubilization [53]. TGF-β1 and TGF-β3 bind to TβRII without participation of type I receptor, whereas TGF-β2 interacts only with combination of both receptors (reviewed in [54]). Although ligand binding may induce autophosphorylation of TβRII cytoplasmic domain, signaling in the absence of TβRI has not been reported [49]. TβRIII betaglycan promotes binding of TGF-β2 to TβRII, since the affinity of TGF-β2 to TβRII is low in the absence of betaglycan [46]. Endoglin binds TGF-β1, TGF-β3 but not TGF-β2 in the presence of the TβRI and TβRII. In some cell types, endoglin was found to inhibit TGF-β signaling – for example in chondrocytes, it enhances TGF-β1-induced SMAD1/5 phosphorylation but inhibits TGF-β1-induced SMAD2 phosphorylation [55].

Ubiquitylation and ubiquitin-mediated degradation define stability and turnover of receptors. Ubiquitylation occurs through sequential actions of E1, E2 and E3 ubiquitin ligases that provide specificity in the ubiquitylation process [56]. The E3 ubiquitin ligases such as Smurf1 and Smurf2 (SMAD ubiquitylation-related factor 1 and 2) regulate the stability of TβRI and heteromeric TGF-β receptor complex [57,58].

Sumoylation, similarly to ubiquitylation, requires E1, E2 and E3 ligases which results in SUMO polypeptide attachment. Although sumoylation has not been observed for any other transmembrane receptor kinases, it was shown to modify TβRI function by facilitating the recruitment and phosphorylation of SMAD3 [59].

TGF-β receptors are also constitutively internalized via clathrin-dependent or lipidraft-dependent endocytic pathways (reviewed in [60]).

R-SMADS and Co-SMAD consist of a conserved MH1 domain (Mad-homology-1) and C-terminal MH2 domain (Mad-homology-2), which are connected by a ‘linker’ segment. The C-terminal domain promotes transcriptional activity, when fused to a heterologous DNA binding domain [62]. On the contrary, I-SMADS contain only the highly conserved MH2 domain. The MH1 domain is responsible for binding to DNA; however, the MH2 domain contains hydrophobic patches also called hydrophobic corridors that allow binding to nucleoproteins, DNA-binding cofactors and various cytoplasmic proteins, as well as interaction with receptors. Both domains can interact with sequence-specific transcription factors. SMAD3 and SMAD4 bind with their MH1 domain to SMAD-binding elements (SBE) on DNA, whereas the common splice form of SMAD2 does not bind to DNA (reviewed in [63]).

I-SMADS function as intracellular antagonists of R-SMADS. Through stable interactions with activated serine/threonine receptors, they inhibit TGF-β family signaling by preventing the activation of R- and Co-SMADs. I-SMADS regulate activation of R-SMADS via binding with their MH2 domain to TβRI, thereby competing with R-SMADS and preventing R-SMADS phosphorylation [64]. SMAD6 is also able to compete with SMAD4 for heteromeric complex formation with activated SMAD1 [65]. Whereas SMAD6 appears to preferentially inhibit BMP signaling, SMAD7 acts as a general inhibitor of TGF-β family signaling. Another possible mechanism of inhibition signaling transduction by I-SMADS is facilitated by HECT type of E3 ubiquitin ligase Smurf1 and Smurf2 [57,58].

Canonical signaling

The SMAD pathway is the canonical signaling pathway that is activated directly by the TGF-β cytokines (Figure 2). TβRII recognizes and phosphorylates signaling effectors – the SMAD proteins. This phosphorylation is a pivotal event in the initiation of TGF-β signal, followed by other steps of signal transduction, subjected to both positive and negative regulation.

R-SMAD binding to the type I receptor is mediated by a zinc double finger FYVE domain containing protein SARA (The SMAD Anchor for Receptor Activation). SARA recruits non-activated SMADs to the activated TGF-β receptor complex [66]. However, TMEPAI (TransMembranE Prostate Androgen-Induced gene/protein), a direct target gene of TGF-β signaling, perturbs recruitment of SMAD2/3 to TβRI and thereby participates in a negative feedback loop to control the duration and intensity of SMADs activation [67]. Receptor-mediated phosphorylation of SMAD2 decreases the affinity of SMAD2 to SARA, leading to dissociation from SARA [68]. Afterwards, phosphorylated complex of

**TGF-β signaling**

**SMAD proteins**
The SMAD proteins are the only known latent cytoplasmic transcription factors that become directly activated by serine phosphorylation at their cognate receptors. SMADs can be classified into 3 groups based on their function: the receptor-regulated SMADs (R-SMADs), SMAD1, SMAD2, SMAD3, SMAD5 and SMAD8; the common SMAD (Co-SMAD), SMAD4, and the inhibitory SMADs (I-SMADs), SMAD6 and SMAD7 (reviewed in [61]).
SMAD2/3 forms a higher-order complex with SMAD4 and moves to the nucleus. At this point, Smurf1 interacts with R-SMADs in order to trigger their ubiquitylation and degradation and hence their inactivation [69]. Further, it was found that Smurf1 and Smurf2 facilitate the inhibitory effect of I-SMADs. Smurf2 binding in the nucleus to SMAD7 induces export and recruitment to the activated TβRIs, where it causes degradation of receptors and SMAD7 via proteasomal and lysosomal pathways [57]. Smurf1 (specific for BMP-SMADs) also interacts with SMAD7 and induces SMAD7 ubiquitylation and translocation into the cytoplasm [58].

For proper translocation to the nucleus, the SMADs contain a nuclear localization-like sequence (NLS-like; Lys-Lys-Leu-Lys) that is recognized by importins [70]. Interestingly, the nuclear translocation of SMADs was also described in vitro to occur independently of added importin-like factors, because SMAD proteins can directly interact with nucleoporins, such as CAN/Nup214 [71,72]. Complex of SMAD2/3 and SMAD4 is retained in the nucleus by interactions with additional protein binding partners and DNA. Dephosphorylation and dissociation of SMAD transcriptional complexes are thought to end this retention, allowing export of R-SMADs out of the nucleus [73].

Different protein binding partners provide another venue for regulatory inputs controlling the activity of SMADs. Each SMAD-partner combination targets a particular subset of genes and recruits either transcriptional co-activators or co-repressors. Members of many DNA-binding protein families participate as SMADs cofactors, such as FOX, HOX, RUNX, E2F, AP1, CREB/ATF, Zinc-finger and other families. The SMAD cofactors differ in various cell types, thereby determining the cell-type dependent responses [63]. By association with DNA-binding cofactors, SMADs reach target gene specificity and target specificity. Stimulation of various cells by TGF-β leads to rapid activation or repression of a few hundred genes; possibly, the pool of activated SMAD proteins is shared among different partner cofactors [74,75].

On chromatin level, SMADs can recruit histone acetyltransferases. Several studies revealed that TGF-β proteins influence transcription of different genes through interaction of the MH1 domain of SMADs with sequence-specific transcription factors and co-activators CBP and p300. CBP and p300 interact with SMAD1, SMAD2, SMAD3 and SMAD4 in vitro and in vivo, and the interaction between the SMADs and CBP/p300 is stimulated in response to TGF-β [76-79]. Moreover, histone deacetylases and chromatin remodeling complexes are also involved in SMAD regulation. In this way, SMADs functionally interact with a variety of transcription factors and regulate diverse signaling pathways as well (reviewed in [80]).

SMADs act as sequence specific transcription factors; however, they can regulate cell fate by alternative mechanisms. Recent data indicate that R-SMADs
associate with the p68/Drosha/DGCR8 miRNA processing complex to regulate miRNA processing in a ligand-dependent and RNA-sequence specific manner. So far, more than 20 TGF-β/BMP-regulated miRNAs (T/B-miRs) have been described [81,82].

Non-SMAD signaling

Diversity of TGF-β signaling in cells is determined not only by various ligands, receptors, SMAD mediators or SMAD-interacting partners, but also by the ability of TGF-β to activate other signaling pathways (Figure 3). TGF-β can indirectly participate in apoptosis, epithelial to mesenchymal transition, migration, proliferation, differentiation and matrix formation (reviewed in [83]). It activates various branches of mitogen-activated protein kinases (MAPK) pathway, such as ERK1/ERK2, Jun-N terminal kinase (JNK) and p38 and PI3K kinases [84]. In response to TGF-β, both SMAD-dependent and SMAD-independent JNK activations are observed [85]. SMAD-independent activation of p38 was observed in mouse mammary epithelial NMuMG cells with mutant TβRI [86].

Other pathways influenced by TGF-β are the growth and survival promoting pathway AKT/PKB, the small GTP-binding proteins RAS, RHOA, RAC1 as well as CDC42 and mTOR [87-89]. TGF-β participates in mediating activation of protein tyrosine kinases FAK, SRC and ABL, particularly in mesenchymal or dedifferentiated epithelial cells [90-92]. TGF-β also influences NF-κB signaling and Wnt/β-catenin pathway [93].

Role of TGF-β in tumors

In tumors, TGF-β can be either a proto-oncogene or a tumor suppressor, depending on cell context and tumor stage [94]. Cancer cells often evade growth inhibition effects of TGF-β, while leaving intact TGF-β-mediated cellular responses that promote tumor progression.

Importantly, the use of mouse models has enabled the elucidation of the dual role of TGF-β in cancer (reviewed in [95]). As homozygous deletions of Tgf-β1, Tgf-β2, Tgf-β3, TβRI and TβRII are lethal in mice, manipulation of TGF-β pathway was achieved mainly through transgene expression or conditional null mutations in vivo [96]. The dual role of TGF-β was shown on a set of experiments with mice skin cancer. The first study demonstrated that TGF-β1 expression targeted to keratinocytes inhibits benign tumor outgrowth; however, later it enhances malignant progression rate and phenotype of the benign papillomas [97]. Study on transgenic mice overexpressing a dominant negative TβRII in the basal cell compartment and in follicular cells of the skin complemented previous results. In non-irritated epidermis of transgenic mice, proliferation and differentiation were normal; however, during tumor promotion, transgenic mice showed an elevated level of proliferation in the epidermis [98]. Furthermore, using mice with inducible expression of TGF-β1 in epidermis confirmed the dual role of TGF-β [99,100].

TGF-β as a tumor suppressor

The most critical effect of TGF-β on target cells is suppression of proliferation. Its growth inhibitory function

![Figure 3 TGF-β non-canonical signaling pathway](image-url)
is based on the ability to suppress expression and function of c-Myc and cyclin-dependent kinases (CDKs) and to enhance expression of the CDK inhibitors p15^INK4B [101] [102] and p27^KIP1 [103].

Cellular responses to TGF-β depend on cell type and physiological conditions. TGF-β stimulates various mesenchymal cell types, including fibroblasts; however, it is a potent inhibitor of epithelial, endothelial, neural cells and hematopoietic cells, including immune cells [10]. Central function of TGF-β is inhibition of cell cycle progression by regulating transcription of cell cycle regulators (Figure 4). Anti-proliferative responses can be induced at any time during cell cycle division; yet, they are effective only in G1 phase. Once a cell is committed to enter replication, it will continue to double its DNA, divide and then arrest when entering the following G1 phase. At this point, TGF-β mediates cell cycle arrest by suppressing expression and function of c-Myc, members of the Id family inhibitors and CDKs and enhancing expression of CDK inhibitors, such as p15^INK4B, p21^CIP1 and p27^KIP1 [104,105].

TGF-β induces the expression of the CDK inhibitor p15^INK4B in a variety of cell types. p15^INK4B is a member of the INK4 family of CDK inhibitors, which binds to CDK4 and CDK6 subunits, inactivates their catalytic activity and prevents cyclin D-CDK4/6 complex formation [101,106]. Furthermore, TGF-β can induce expression of p21^CIP1 in several cell types [107,108]. Other CDK inhibitory responses, observed in several cell types after exposure to TGF-β, are inhibition of CDK4 expression and down-regulation of CDC25A expression [109].

Low levels of c-Myc allow for TGF-β induced transcription of p15^INK4B and p21^CIP1 genes. Decreased expression of c-Myc in keratinocytes is mediated by SMAD3 in association with transcription factors E2F4 and E2F5, p107 co-repressor and SMAD4 [110]. On the other hand, down-regulation of Id proteins in epithelial cells is due to activated SMAD3 that induces activating transcription factor (ATF) expression and then together with ATF directly represses the Id promoter [104].

**TGF-β as a tumor promoter**

TGF-β acts as tumor suppressor in normal epithelium; it inhibits cell proliferation and induces apoptosis. Yet, during tumor progression, sensitivity to these effects of TGF-β is frequently lost and, in later stages, TGF-β signaling has pro-oncogenic function. Several activities have been described to TGF-β that would favor tumor progression [111].

**Mutations in signaling components**

Malignant cells become resistant to suppressive effects of TGF-β either through mutation and/or functional inactivation of TGF-β receptors or by downstream alterations in the SMAD-signaling pathway. During late stages of tumor progression, TGF-β acts as tumor promoter and is often over-expressed in many cancers. Elevated plasma level of TGF-β1 was observed in hepatocellular carcinoma.

---

**Figure 4 Role of TGF-β in regulation of cell cycle.** Physiologically, TGF-β is a potent inhibitor of cell cycle; it induces expression of p15^INK4B and represses expression of c-Myc. p15^INK4B is able to prevent cyclin D-CDK4/6 complex formation; moreover, it displaces p21^CIP1 and p27^KIP1 from cyclin D-CDK4/6 complexes. These CIP/KIP inhibitors are subsequently able to inactivate other complexes of G1 and S phase and thereby inhibit cell cycle. Moreover, low levels of c-Myc allows for TGF-β induced p15^INK4B and p21^CIP1 transcription.
carcinoma, colon, HCC, prostate, lung and breast cancers and correlates with poor prognosis [112].

Mutations in downstream TGF-β signaling components cause variable attenuations or complete loss of expression; these mutations, which have been detected in many common tumors, affect TGF-β signal transmission that potentially results in human cancer development and progression. In particular, TβRI, TβRII, SMAD2 and SMAD4 are frequently lost, mutated or attenuated (gene/LOH/expression). Inactivation of TβRII leads to increased tumor spreading and metastasis in a variety of carcinomas, including colon [113], breast [114], pancreatic [115], intestinal [116] or head and neck squamous cell carcinoma (HNSCC) [117]. Also, deregulated expression or aberrant function of Smurf1 and 2 was described. Several human carcinoma cell lines such as colon HT-29, breast MDA-MB-231, gastric MKN-1 and ovarian OVCAR-5 display high levels of one or more E3 ligases, including Smurf2 [118,119]. Moreover, in esophageal squamous carcinoma, high expression levels of Smurf2 associated with low levels of SMAD2 phosphorylation were detected [120]. Furthermore, TGF-β pathway is modulated by epigenetic mechanisms, such as transcriptional repression of TβRII, DNA methylation of TβRI and TβRII and histone modifications [121-123].

**TGF-β in tumor microenvironment and metastases**

Tumor metastases accounts for the majority of cancer associated deaths. Recent evidence strongly suggests that tumor microenvironment is essential in this process. It consists of tumor cells and a variety of immune cells, which infiltrate into tumors. This dynamic microenvironment is not only important for cross-talk with tumor cells or escape of tumor from host immune surveillance, but it also induces formation of new blood vessels and invades the vasculature. Areas of hypoxic tissue are thought to drive genomic instability and alter DNA damage repair [124]. Recent studies suggest that TGF-β is one of the critical regulators of inflammation; it is thought that tumor metastasis is a coordinated process between tumor cells and host cells through inflammation [125]. However, it seems that different mechanisms are implemented in different tumor type.

TGF-β as a proto-oncogene is important in stromal-epithelial cross-talk, as was shown for the first time in mouse experiments, where deletion of the TβRII in stromal fibroblasts resulted in transformation of adjacent epithelia of prostate and forestomach. Moreover, in this model, hepatocyte growth factor (HGF) was up-regulated and complementary activation of the HGF receptor MET was detected in tissues where TβRII had been ablated, which implicates this paracrine signaling network as a potential mechanism for regulation of carcinoma development [126]. Further experiment performed on these mice revealed that mice fibroblasts have up-regulated expression of growth factors and increased proliferation of mammary cancer cells [127]. Together, it indicates that TGF-β responses mediated by stromal fibroblasts can regulate carcinoma initiation and progression of adjacent epithelium in vivo and in vitro.

Interestingly, it was found that TGF-β in breast cancer favors metastasis to lungs. TGF-β stimulation of mammary carcinoma cells in tumor microenvironment, before they enter circulation, primes these cells for seeding of lungs through a transient induction of angiopoietin-like4 (Angptl4) via canonical signaling pathway [128]. TGF-β is involved in regulation of chemokines and chemokine receptors which take part in inflammatory cells recruitment. The loss of TβRII in breast cancer cells can enhance recruitment of F4/80+ cells to tumor microenvironment and increase the expression of pro-inflammatory genes, including CXCL1, CXCL5 and PTGS2 (cyclooxygenase-2). Further, in vitro treatment of carcinoma cells with TGF-β suppressed the expression of CXCL1, CXCL5 and PTGS2 [129].

Different mechanism was observed in gastric carcinoma, where SMAD-dependent TGF-β pathway, in collaboration with PKC-δ expression and phosphorylation and integrin expression and activation, regulates cell invasion and cell spreading [130].

Beside the effects already mentioned, TGF-β is broadly implemented in induction of epithelial-to-mesenchymal transition [131]. The NBT-II cell line, derived from a chemically induced rat bladder carcinoma, forms epithelial colonies that can be converted into migratory mesenchymal cells within a few hours by adding Tgf-β and other factors, such as Fgf1, Fgf7, Fgf10, Egf, Igf1, Igf2 or Hgf [132].

**TGF-β as a regulator of immune cells**

The tumor microenvironment is filled with various inflammatory cells, including myeloid cell subpopulations, T cells and B cells. TGF-β is one of the most potent endogenous negative regulators of hematopoiesis. It modulates proliferation, differentiation and function of all types of lymphocytes, macrophages and dendritic cells, thus regulating the innate, non-antigen-specific as well as antigen-specific immunity [133].

TGF-β is involved in normal B cells maturation and differentiation, such as regulation of expression of cell-surface molecules, inhibition of IgM, IgD, CD23 and the transferrin receptor and induction of MHC class II expression on pre-B cells and mature B cells [134].

In T cells, TGF-β regulates maturation; for example, it is released by regulatory T cells and inhibits the Ag-specific proliferation of naive CD4+ cells from T cell receptor (TCR) [135]. TGF-β1 also inhibits aberrant T cell expansion by maintaining intracellular calcium
concentration levels low enough to prevent mitogenic response by Ca\(^{2+}\)-independent stimulatory pathways [136].

In myeloid cells, such as macrophages and monocytes, TGF-β1 is mostly suppressive, it inhibits cell proliferation and down-regulates production of reactive oxygen and nitrogen intermediates; however, it is able to enhance some other activities of myeloid cells. TGF-β1 can be recognized by monocytes and macrophages as a chemotactic factor; it induces direct monocytes migration in vitro [137].

TGF-β pro-metastatic and pro-inflammatory effects are regulated via nuclear factor kappa B (NF-κB), the master regulator of inflammation and a regulator of genes that controls cell proliferation and cell survival. TGF-β1 is a negative regulator of NF-κB activation, as was shown in the gut; it directly stimulates IκB-α promoter transcriptional activity in vitro. However, SMAD7 maintains high NF-κB activity by blocking TGF-β1 signaling [138].

**Targeting the TGF-β signaling pathway**

As the signaling pathway deregulations are responsible for cancer initiation and progression, interrupting the tumor promoter properties of TGF-β signaling would be an attractive therapeutic strategy, without altering physiologic tumor suppressor functions exhibited in early stages of tumorigenesis. Strategies such as using monoclonal TGF-β-neutralizing antibodies, large molecule ligand traps, reducing translational efficiency of TGF-β ligands using antisense technology and antagonizing TGF-β receptor I/II kinase function by small molecule inhibitors are the most prominent methods being explored today [139,140]. Furthermore, studies have shown that combined treatment with tumor cell vaccines and antisense TGF-β therapy reduced tumor size and increased survival benefit [141,142]. Preclinical studies also show that TGF-β inhibition can augment therapeutic efficacy of cytotoxic agents [143]. However, as there are still potential limitations and risks of TGF-β targeted therapy, caution must be given as to when, how and how much therapy would be beneficial or how much toxicity will be induced by chronically administered therapy. However, daily administration of a high dose of neutralizing TGF-β antibody in adult mice for 12 weeks and a lifetime exposure to soluble TβRII (sTβRII) in transgenic mice did not significantly affect their health. This suggests that anti-TGF-β treatments are likely to be safe [144].

**TGF-β in solid tumors**

**Brain tumors**

TGF-β has a suppressive role in physiological development of the central nervous system (CNS); all TGF-β isoforms and receptors necessary for TGF-β signal transduction are detected in developing as well as adult CNS [145].

The most aggressive type of primary brain tumors, glioblastoma multiforme (GBM), is characterized by poorly differentiated and highly proliferating cells that originate from glial cells [146,147]. Here, the release from cytostatic TGF-β effect is explained by a broad range of inactivating mutations in the TGF-β1 signaling pathway. Several studies describe mutations in TβRI and TβRII in adenomas and gliomas [148,149] as well as correlation between higher expression of TβRI and TβRII with more aggressive glioma cell lines and tumors [150,151]. Moreover, high levels of TGF-β indicate that TGF-β is able to induce its own expression and thereby create a malignant autocrine loop and control glioma-cell proliferation [152]. Alterations of SMAD protein levels and activation were reported in brain tumor cell lines and patient samples. In glioma cell lines, SMAD3 level and SMAD2 nuclear translocation was lower in 9 out of 10 cell lines [153]. Kjellman et al. reported that SMAD2, SMAD3 and SMAD4 mRNA levels were reduced in GBM samples in comparison to normal brain samples, astrocytomas and anaplastic astrocytomas [150]. Nevertheless, these data are controversial to a study in which higher phospho-SMAD2 (p-SMAD2) level correlated with higher grade of glioma [154]. Further analysis of cell lines and patient samples would elucidate such discrepancies.

**Urogenital tumors**

TGF-β is a crucial molecule in the genesis of urogenital tumors, such as urinary bladder carcinoma, renal cell carcinoma, ovarian and prostate cancers [155].

The TGF-β pathway is involved in urinary bladder cancer progression. The amount of secreted TGF-β correlates with more aggressive phenotype of cell lines. In addition, deregulated TGF-β signaling led to enhanced migration and invasiveness of bladder cancer cells [156]. Silencing of TβRII expression by siRNA led to significant inhibition of TGF-β1-induced signal transduction and thereby reduced invasiveness of bladder cancer cells [157].

Clear cell renal cell carcinoma (CCRCC) is the most common malignancy of the kidney; it accounts for 2-3% of all malignant diseases in adults [158]. In CCRCC patient samples, sequential loss of TβRII and TβRIII expression was associated with renal cell carcinogenesis and progression [155]. Cross-talk between Notch signaling and TGF-β pathway contributes to aggressiveness of CCRCC. Recently, it was described that inhibition of Notch signaling leads to attenuation of basal TGF-β-induced signaling in CCRCC cells; it also influenced genes involved in cancer migration [159].
Ovarian cancer

In advanced ovarian tumors, low expression of TGF-β1 mRNA is connected to better prognosis. It was found that TGF-β1 mRNA expression was significantly lower in tumors of patients who had optimal surgery than in patients with suboptimal surgery. TGF-β1 mRNA expression was also significantly lower in tumors with high sensitivity to chemotherapeutics than in those with low sensitivity [160].

Alterations in the TβRI gene occur in ovarian cancer and account, at least in part, for the frequent loss of TGF-β responsiveness of these cancer cells. Presence of TβRI 67A allele in about 27% of human ovarian cancers suggests that it acts as a low penetrating tumor marker in the development of ovarian cancer [161-163].

Mutations in the TβRII allele that cause loss or decrease in TβRII protein level are also present, BAT-RII mutations (mutations in polyadenine tract in exon 3) were found in 22% of ovarian tumors [161]. Although this mutation is connected to microsatellite stability, in ovarian cancers this association remains controversial [164].

Mutations in SMAD4 are not very common in ovarian cancer but were reported in primary cultures or cell lines [165]. Reduced expression or loss of SMAD4 protein leads to decreased ability to bind DNA; SMAD4 inactivation is involved in the acquisition of a more aggressive tumor [161].

It has been suggested that SMAD4 and SMAD3 are involved in metastatic potential of ovarian cancers [166,167]. In ovarian cancer cell lines, TGF-β supported metastatic activity at least partly through activation of MMPs [168]. Deregulation in TGF-β/SMAD4 signaling leads to epigenetic silencing of a putative tumor suppressor, RunX1T1, during ovarian carcinogenesis [169]. Recently, genome-wide screening done by ChIP-seq of TGF-β-induced SMAD4 binding in epithelial ovarian cancer revealed that SMAD4-dependent regulatory network was strikingly different in ovarian cancer compared to normal cells and was predictive of patients survival [170].

Breast cancer

In normal mammalian breast development, all TGF-β isoforms are functionally equivalent; they are all involved in establishing proper gland structures and apoptosis induction. However, they have distinct roles in mammary growth regulation, morphogenesis and functional differentiation [180-182].

In breast cancer, results evaluating TGF-β as a prognostic factor are controversial. On the one hand, analysis demonstrated TGF-β1 expression to be significantly higher in patients with a favorable outcome as compared to patients with a poor prognosis [183]. On the other hand, several studies showed that TGF-β over-expression is related to worse outcome [184,185]. Elevation of TGF-β has been shown to participate in breast cancer metastasis [186].

Alterations of TGF-β signaling molecules are relatively rare, except for TβRII down-regulation. No specific mutations were found in the coding or in the regulatory region of the TβRII gene promoter in breast cancer [187,188]. However, the loss of TβRII expression has been linked to tumor progression and metastasis, principally in HER2-negative patients [114]. In addition, resistance of breast cell lines to TGF-β may be due to reduced expression of TβRII [189]. Mutations of TβRII are rare among breast cancer patients, while changes in receptor expression may take part in tumor progression [187]. Opposite to TβRII, intragenic mutations occur in TβRI and are associated with metastatic breast cancer [190].

Although the role of TβRIII remains unclear, it seems that this receptor is a suppressor of breast cancer. Loss of TβRIII through allelic imbalance is a frequent genetic
event during human breast cancer development that increases metastatic potential; moreover, decreased TβRIII expression correlates with decreased recurrence-free survival in breast cancer patients [191].

Mutations in downstream signaling pathway including SMAD proteins are not very common in breast cancer; however, inactivating mutations or loss of expression in SMAD4 have been described [164,192].

Tumors of the digestive tract

Gastric cancer

Resistance to TGF-β is a hallmark of gastric cancer. The relationship between TGF-β resistance and up-regulated level of miR-106b-25 cluster (miR-106b, miR-93, and miR-25) has been recently elucidated [193]. The cluster is an intronic part of the Mem7 gene and thus is regulated by E2F1. Conversely, miR-106b and miR-93 control E2F1 expression thus establishing negative feedback that prevents E2F1 self-activation. Over-expression of miR-106b, miR-93 and miR-25 decreases response of gastric cancer cells to TGF-β since they interfere with synthesis of TGF-β downstream effectors that promote cell cycle arrest and apoptosis, such as p21CIP1 and BIM, respectively [193] (Figure 5).

Mutations in TβRII that lead to insensitivity of cell lines to TGF-β mediated growth inhibition have been previously described [194]. It has been shown that conditional loss of TGF-β signaling due to dominant negative mutation in TβRII leads to increased susceptibility to gastrointestinal carcinogenesis in mice [195].

Epigenetic changes in TβRI are another important mechanism of escape from TGF-β physiological function. Hypermethylation of a CpG island in the 5′ region of the TβRI was found in 80% of gastric cancer cell lines and 12.5% of primary tumors. Treatment with demethylating agent increased expression of TβRI and transient transfection of TβRI into TGF-β resistant cell line restored TGF-β responsiveness [123].

Effects of TGF-β on gastric cancer invasiveness and metastasis are mediated by activation of JNK and ERK pathways which support expression of fascin-1, an actin-binding protein. Moreover, signaling pathway based on SMAD proteins is not involved in this process because transitional repression of SMADs did not alter fascin-1 expression [196].

Nevertheless, impaired signaling based on SMAD proteins also occurs in gastric cancer. Shinto et al. found a correlation between expression level of p-SMAD2 and patients prognosis. P-SMAD2 protein expression level was significantly higher in patients with diffuse form of carcinoma and metastatic tumors and is associated with worse outcome [197]. TGF-β signaling is also abrogated by decreased expression of SMAD3. Low or undetectable level of SMAD3 was observed in 37.5% of human gastric cancer tissues. In cell lines, which showed deficient expression of SMAD3, introduction of SMAD3 gene led to growth inhibition caused by TGF-β [198].

Sonic hedgehog (Shh), a member of the hedgehog signaling pathway, promotes invasiveness of gastric cancer through TGF-β-mediated activation of the ALK5–SMAD3 pathway. Higher concentrations of N-Shh (human recombinant form of Shh) enhanced cell motility and invasiveness in gastric cancer cells; moreover, treatment of cells with N-Shh led to enhanced TGF-β1 secretion, TGF-β-mediated transcriptional response, expression of ALK5 protein and phosphorylation of SMAD3. Effect of Shh on cell motility was not observed after treatment of cells with anti-TGF-β blocking antibody or TGF-β1 siRNA [199].

Hepatocellular carcinoma

Reduced TβRII expression was observed in approximately 25% of hepatocellular carcinoma (HCC) patients; this event is associated with aggressive phenotype of HCC and intrahepatic metastasis. TβRII down-regulation also correlated with an early recurrence time and higher grade of tumor suggesting that TβRII down-regulation is a late event in HCC development. In addition, TGF-β is a tumor suppressor in the majority of HCCs expressing TβRII [200].

Mutations in intracellular signaling components have been observed: SMAD2 mutations occur in 5% of HCC, while loss of SMAD4 expression was found in 10% of HCC [201,202].

Several studies of HCC indicated that over-expression of SMAD3 promotes TGF-β-induced apoptosis [203,204]. Pro-apoptotic activity of SMAD3 requires both input from TGF-β signaling and activation of p38 MAPK, which occurs selectively in liver tumor cells. SMAD3 represses transcription of an important apoptotic inhibitor, BCL-2, by directly binding to its promoter [203].

Therapeutic options for patients with HCC are still limited; however, it was recently described that blocking the TGF-β signaling pathway with LY2109761, a kinase inhibitor of TβRI, is associated with inhibition of molecular pathways involved in neo-angiogenesis and tumor growth. LY2109761 interrupts the cross-talk between cancer cells and cancer-associated fibroblasts, leading to significant reduction of HCC growth and dissemination. Currently, LY2109761 is being tested in clinical trial phase II [205-207].

Colorectal cancer

In colorectal cancer (CRC), TGF-β1 inhibits proliferation of less aggressive tumor cells but stimulates growth of tumor cells at later stages by autocrine manner. High level of TGF-β1 correlates with tumor progression [208]. In colorectal cell lines, TGF-β induces proliferation by
In a recent study, TGF-β, TβRI, TβRII, SMAD4, pSMAD2/3 and E-cadherin were found to be closely related to TNM stage of CRC. Therefore, TGF-β, TβRII, SMAD4, pSMAD2/3 and E-cadherin come into view as valuable independent biomarkers of prognosis in CRC patients [140].

Inactivating mutations in SMAD2 and SMAD4 are frequent especially in pancreatic and colorectal carcinomas, although they do not stand for the most frequent tumor changes. Most of SMAD2 mutations have been found in the MH2 protein domain, thereby preventing complex formation with SMAD3 and SMAD4. Alterations of SMAD2 are present in about 6% of colorectal carcinoma cases [210]. SMAD3 mutation is a very rare event in human solid tumors; however, a missense mutation in SMAD3 gene (leading to reduced activity of SMAD3 protein) was found in human colorectal cell lines [211]. Inactivation of SMAD4 is a genetically late event in gastrointestinal carcinogenesis. It was identified with less frequency in advanced colon cancers and in 16% of colon carcinomas [212,213]. Nevertheless, recent studies revealed that some of the TGF-β induced pathways are SMAD4 independent [214]. Proteomic screen of SMAD4 wt and SMAD4 deficient cell lines detected different protein levels in cell lines pointing to SMAD4 dependent and independent TGF-β responses in colon carcinoma cells [215]. Another study indicated that novel genetic variant -4 T(10) in the SMAD4 gene promoter affects its activity. Obtained preliminary results indicate that SMAD4 gene promoter haplotype -462 T(14)/-4 T(10) represents a potentially relevant genetic marker for pancreatic and colorectal cancer [216]. This downstream inactivation of TGF-β signaling components promotes colon adenoma to carcinoma progression.

Mutations of TβRII are frequent alterations of the TGF-β signaling pathway (reviewed in [217]). They are present in approximately 30% of CRC cases and were reported in cancer cell lines, sporadic colon cancers and patients with hereditary non-polyposis colorectal cancer with microsatellite instability and in a smaller percentage in microsatellite stable cancers [123,218,219]. TβRII mutations occur in >90% of microsatellite unstable (MSI) colon cancers and most principally affect a polyadenine tract in exon 3 of TβRII, the BAT-RII; however, non-BAT point mutations in TβRII were found with less frequency also in microsatellite stable cancers [164,219]. Interestingly, it has been recently published that restoration of TβRII in cancer cell lines with microsatellite instability (MSI), bearing mutated TβRII, promoted cell survival and motility. Therefore, it is plausible that such mutations contribute to favorable outcome in MSI patients [220].

In contrast to TβRII, mutations in TβRI are less common. They are rare in colon as well as pancreatic cancer.

Figure 5 The E2F1/miR-106b-25/p21 pathway. In gastric cancer, miR-106b-25 cluster is activated by E2F1 in parallel with its host gene, Mcm7. In turn, miR-106b and miR-93 regulate E2F1 expression, establishing a miRNA negative feedback loop. Over-expressed miR-106b, miR-93, and miR-25 inhibit the synthesis of p21TIP1 and Bim (TGF-β downstream effectors) and therefore prevent cell cycle inhibition and apoptosis.
Decreased TβRI allele expression is associated with higher risk of colon cancer development [221]. Recently, it has been described that TβRIII mRNA expression is not significantly altered in human colorectal cell lines; however, protein levels of TβRIII are frequently increased, suggesting a distinct role for TβRIII in colon cancer. Thus, enhanced expression of TβRIII is possibly involved in cancer progression [222].

Other mechanisms, such as crosstalk between TGF-β and Wnt/β-catenin pathways, are involved in colon cancer progression [214]. It has been shown that SMAD4 restoration is associated with suppression of Wnt/β-catenin signaling activity, decrease of β-catenin/Tcf target genes expression and with induction of functional E-cadherin expression [223].

Recently, the role of microRNA in colon cancer has been established. Elevated levels of miR-21 and miR-31 promote motility and invasiveness of colon cancer cell line and enhance the effect of TGF-β. It seems that miR-21 and miR-31 act as downstream effectors of TGF-β [224].

Pancreatic cancer
Pancreatic cancer has the poorest prognosis among GI cancers due to aggressiveness, frequent metastases and resistance to treatment. SMAD4, also called DPC4 (deleted in pancreatic carcinomas), suggests close relationship between loss of this gene and pancreatic cancer. Mutation or deletion of SMAD4 is a well-characterized disruption in between loss of this gene and pancreatic cancer. Mutation or inactivation in 20%, while all of cases [225]. These mutations are present mostly in approximately 30% of cases, inactivated in 20%, while allelic loss of the whole 18q region was found in almost 90% of cases [225]. These mutations are present mostly in the MH2 domain; however, missense, nonsense or frame-shift mutations are present within the MH1 domain as well [226,227].

Dual role of SMAD4 was established in a mouse model. Smad4 or TβRII deletion in pancreatic epithelium did not affect pancreatic development or physiology. However, when activated K-Ras was present in cells, loss of Smad4 or TβRII or Smad4 haploinsufficiency led to progression to high-grade tumors. Thus, it is possible that Smad4 mediates the tumor inhibitory action of TGF-β signaling, mainly in the progressive stage of tumorigenesis [115].

In concordance with colorectal cancer, mutations in TβRII were found in cancers with microsatellite instability; however, mutations in TβRII and also in TβRI are less common [217]. Frequency of mutations in TβRII is about 4% and even less for TβRI [228]. Interestingly, polymorphism within the TβRI gene, which is less effective in mediating anti-proliferative signals than wild type, was described [229].

High level of TGF-β was found in serum of patients with pancreatic adenocarcinoma suggesting that TGF-β could possibly become a marker for monitoring disease activity [230].

As previously mentioned in HCC, targeting TβRII/II kinase activity in pancreatic cancer with the novel inhibitor LY2109761 also suppressed pancreatic cancer metastatic processes. LY2109761 suppressed both basal and TGF-β1-induced cell migration and invasion and induced anoikis. In vivo, LY2109761, in combination with gemcitabine, significantly reduced the tumor burden, prolonged survival and reduced spontaneous abdominal metastases [231].

Lung cancer
In non-small cell lung carcinoma (NSCLC), elevated expression of TGF-β correlates with disease progression [232]. Furthermore, significantly higher serum concentrations of TGF-β1 cytokine were found in lung cancer patients. Presumably, elevated expression and higher levels of serum TGF-β represent an important prognostic factor that could serve as a complementary diagnostic test in lung cancer detection [233].

Defective expression of TβRII was observed in primary NSCLC, where TβRII acts as a tumor suppressor. Down-regulation of TβRII on transcriptional level could be explained by aberrant methylation of the TβRII promoter [234]. Moreover, reduced expression of TβRIII has been found in NSCLC cells compared to normal human bronchial epithelial cells [235].

Downstream components of TGF-β signaling pathways are important in NSCLC development. Jeon et al. observed a correlation between better tumor-related survival and absence of SMAD6. Moreover, SMAD6 contributes to lung cancer progression by limiting TGF-β-mediated growth inhibition of cell lines, which was proven by knockdown of SMAD6 that resulted in increased apoptosis in lung cancer cell line [236].

TGF-β signaling is also required for lung adenocarcinoma (LAC) progression. In a study on LAC cell line A549, knockdown of TβRII resulted in suppression of cell proliferation, invasion and metastasis and induced cell apoptosis [237].

TGF-β in hematological malignancies
Leukemia
Myeloid leukemia
TGF-β is a potent inhibitor of human myeloid leukemia cells [238]. In acute myeloid leukemia (AML), t(8;21) translocation results in the formation of a chimeric transcription factor AML1/ETO. Jakubowiak et al. used transient transfection assays and a reporter gene
construct that contained SMAD and AML1 consensus binding sequences and demonstrated that AML1/ETO represses basal promoter activity function and blocks response to TGF-β1. AML1/ETO possibly binds to SMAD3, instead of activating TGF-β1 signaling pathway. It represses TGF-β1-induced transcriptional activity and blocks TGF-β1 signaling, thus contributing to leukemia genesis [239].

In addition, in AML, dominant negative mutations in SMAD4 were found. They are characterized by a missense mutation in the MH1 domain and a frameshift mutation in the MH2 domain of SMAD4. Mutated SMAD4 lacks transcriptional activity [240].

The t(3;21) translocation fusion product AML1/EVI-1 likely interacts with SMAD3 through the first zinc finger domain, represses SMAD3 activity by preventing SMAD3 from interacting with DNA, thereby repressing TGF-β-mediated growth suppression in hematopoietic cells. This way, AML1/EVI-1 contributes to leukemogenesis [241].

In acute promyelocytic leukemia (APL), t(15;17) translocation in which the retinoic acid receptor α (RARα) gene on 17q22 fuses with a nuclear regulatory factor PML on 15q22 results in the fusion protein PML-RARα [242]. PML is normally found in 2 isoforms, a nuclear isoform and a cytoplasmic isoform. Cytoplasmic isoform is required for association of SMAD2/3 with SARA and for the accumulation of SARA and TGF-β receptors, resulting in SMAD phosphorylation (Figure 6). The PML-RARα oncprotein antagonizes with cytoplasmic PML function by withdrawing cytoplasmic PML from the SMAD2/3-SARA [243].

In chronic myeloid leukemia (CML), t(9;22) (the so-called Philadelphia chromosome) results in the formation of BCR-ABL fusion gene [244]. The fusion protein is an active tyrosine kinase which enhances resistance of malignant cells to TGF-β-induced growth inhibition and apoptosis. BCR-ABL protein targets AKT and transcription factor FOXO3 and thus impairs the cytostatic effect of TGF-β1 [245]. In addition, by improving proteosomal degradation, BCR-ABL blocks TGF-β1-induced expression of p27KIP1. Thus, BCR-ABL kinase promotes activation of cyclin-dependent kinase and cell cycle progression [246].

In CML, expression of EVI-1, a proto-oncogene that is expressed at very low levels in normal hematopoietic cells, is increased. [247]. EVI-1 binds to the MH2 domain of SMAD3 repressing its DNA-binding ability and transcriptional activity and this way attenuates TGF-β signaling [248].

Moller et al. showed that BCR-ABL up-regulates TGF-β signaling when expressed in Cos-1 cells. In Cos-1 cells, the expression of BCR-ABL up-regulates TGF-β-mediated transcriptional activity by interaction between TβRI and kinase domain of BCR-ABL, which leads to increased activity of SMAD3 promoter and increased SMAD2 and SMAD3 protein expression level [249].

Lymphoid leukemia

In children T-cell acute lymphoblastic leukemia (ALL), SMAD3 protein is absent or significantly decreased, however SMAD3 mRNA is present in T-cell ALL and normal T-cells at similar level. The level of SMAD3 is decisive for the T-cell response to TGF-β. A reduction in SMAD3 interplays with other oncogenic events, such as alterations in the retinoblastoma pathway, to precede T-cell leukemogenesis. It was proven that the loss of Smad3 can work in tandem with a loss of p27KIP1, which is also frequently altered in human T-cell ALL, to promote T-cell leukemogenesis in mice [250].

The t(12;21) translocation found in ALL generates the TEL-AML1 chimeric protein. Loss of sensitivity to TGF-β...
β could be an important component of the function of TEL-AML1; it was shown that TEL-AML1 blocks the ability of TGF-β to suppress proliferation via activation of p27^KIP1. The exact mechanism needs to be elucidated; however, a possible alternative is that TEL-AML1, in addition to binding SMAD3, binds co-repressors NcoR and SIN3A and this complex is able to transcriptionally activate the key cell cycle negative regulators, including p27^KIP1[251].

Scott et al. showed that mRNA of downstream components of TGF-β pathway, such as p21^{CIP1} and p15^{INK4B}, are absent in ALL cell lines with high frequency, while p27^KIP1 mRNA levels are not reduced. These findings suggest epigenetic silencing of TGF-β signaling in molecular pathogenesis of ALL and possibly p15^{INK4B} and p21^{CIP1} are inactivated by this mechanism. In ALL, p15^{INK4B} mRNA absence is often connected with promoter methylation, whereas reduced p21^{CIP1} expression happens independently of promoter methylation, indicating that within the same malignancy, epigenetic silencing of TGF-β signaling is methylation-dependent or independent [252].

In adult acute T-cell leukemia, TGF-β signaling is inactivated through the activity of viral oncoprotein Tax. This oncoprotein compromises trans-activation of TGF-β responsive promoters by inhibiting the ability of SMAD proteins to mediate TGF-β-induced transcriptional activation by interfering with transcriptional factor CBP/p300 [253]. Another model of its function is that Tax interacts with the MH2 domains of SMADs 2, 3 and 4 in order to inhibit formation of the SMAD3/4 complex, disturb the interplay of the SMAD proteins with transcriptional factor CBP/p300, prevent binding of the SMAD complex to its target DNA sequence and thus inhibit TGF-β signaling [254]. The Tax repressor effect is mediated by activating JNK leading to increased phosphorylation of c-Jun, which is followed by formation of SMAD3/c-Jun complex that inhibits the ability of SMAD3 to bind DNA [255].

In hairy-cell leukemia (HCL), higher levels of TGF-β1 were observed in bone marrow (BM), serum and plasma from peripheral blood. The main source of this cytokine in active and latent form is hairy cell (HC). HCs produce TGF-β1, which is stored in BM near bone marrow fibroblasts; it activates them to synthesize collagen and reticulin fibers. TGF-β1 is important in fibrosis and is directly involved in the pathogenesis of BM reticulin fibrosis in HCL [256].

Lymphoma

Peripheral and cutaneous T-cell lymphoma

In cutaneous T-cell lymphoma and Sézary syndrome, reduced levels of TβRI and TβRII correlate with decrease in TβRI and TβRII mRNA levels. This leads to the loss of TGF-β growth inhibitory responses [257].

Knaus et al. detected a single point mutation (Asp-404-Gly [D404G]) in the kinase domain of TβRII in advanced lymphoma. This dominant negative mutation prevents cell surface expression of normal TβRII. The ability of the mutant receptor to prevent function of normal TGF-β receptors is a new mechanism for loss of responsiveness to the TGF-β in tumorogenesis. Since TβRI is not able to bind TGF-β in the absence of TβRII, no TβRI is detected on the surface of these cells. This mutant receptor binds to normal receptor in an intracellular compartment, likely the endoplasmic reticulum, and blocks development of the normal receptor on the cell surface [258]. In addition, a 178-bp deletion in exon 1 in the gene for TβRI was reported to be responsible for loss of TβRI expression on the cell surface in anaplastic large cell lymphoma cell line JK. This deletion was confirmed to be present also in patients’ samples. Also, loss of TβRI is followed by loss of its tumor suppressive properties in human T-cell lymphoma [259].

Non-Hodgkin’s lymphomas (NHL)

ATL, adult T-cell leukemia/lymphoma is a rare form of Non-Hodgkin’s lymphoma (NHL). Zinc-finger E-box binding homeobox 1 (ZEB1) is a candidate tumor suppressor gene since mRNA of ZEB1 was found to be down-regulated in ATL. Physiologically, ZEB1 binds phosphorylated SMAD2/3 to enhance TGF-β signaling, and it can counteract the SMAD7-mediated inhibition of TGF-β1 function. Down-regulation of ZEB1 mRNA together with over-expression of inhibitory SMAD7 mRNA in ATL leads to loss of responsiveness to TGF-β-mediated growth arrest. Therefore, ZEB1 has an important role in regulation of TGF-β1 signaling pathway by binding to R-SMADs and also I-SMADs [260].

SMAD1 protein level is elevated and it is phosphorylated in response to TGF-β1 signaling in NHL. This suggests a role of SMAD1 in mediating the effects of TGF-β in NHL [261].

In B-cell lymphoma, Bakkebo et al. found that phosphorylation of SMAD1/5 is surprisingly an important event for the TGF-β-mediated anti-proliferative effects. TβRI was highly expressed in these cells and likely is important for signaling through SMAD1/5 pathway. Also, the regulation of TGF-β-mediated proliferation is at least partly dependent on activated p38 MAPK [262]. In B-cell lymphoma, the cell line resistant to TGF-β1 did not possess functional TβRII. This led to the absence of nuclear translocation of phosphorylated SMAD3 and SMAD2, the lack of nuclear expression of p21^{CIP1} and the down-regulation of c-Myc. Chen et al. found that methylation of promoter (CpG methylations at −25 and −140) plays an important role in TβRII gene silencing [263].
In diffuse large B-cell lymphoma (DLBCL), miR-155, which is over-expressed in aggressive type of B-cell lymphoma, targets SMAD5 by binding to the 3' UTR of the SMAD5 gene. Treatment of DLBCL cell line with TGF-β1 resulted in phosphorylation of SMAD2/3 but also of SMAD1/5 indicating an active non-canonical signaling. Over-expression of miR-155 in this cell line significantly limited the cytostatic effect of cytokine due to impaired TGF-β1-mediated induction of p21CIp1. In miR-155-overexpressing and SMAD5 knockdown DLBCLs, the disruption of p21CIp1 induction was independent of the inhibitory effects of TGF-β1 thus creating a link between miR-155, TGF-β pathway and lymphogenesis [264].

In small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), the CLL cells are resistant to the growth-inhibitory effects of TGF-β in spite of TβRII expression which is similar as in normal B cells. Therefore, the loss of responsiveness to TGF-β is most likely due to altered binding of TGF-β to the receptor complex or downstream signaling pathway [265]. Lagneaux et al. attributed the loss of responsiveness of CLL cells to TGF-β especially to decreased cell-surface expression of TβRI. CLL cells resistant to TGF-β1 showed no surface TβRI able to bind TGF-β1, but the expression of TβRII was normal. On the other hand, both TGF-β1-sensitive and TGF-β1-resistant CLL cells contained normal levels of TβRI and TβRII mRNAs. The absence of functional TβRI on the surface of CLL cells, in spite of normal mRNA level, could be explained by point mutations in the TβRI gene [266,267].

In CLL, Schiemann et al. found mutations in the signal sequence of TβRI (Leu12Gln substitution together with an in-frame single Ala deletion) which leads to reduced gene transcription stimulated by TGF-β [268]. In addition, CLL cells exhibited an increased expression of the TGF-β co-receptor, TβRIII, which is normally not expressed entirely in hematopoietic cells [269]. On the other hand, Lotz et al. found over-expression of TGF-β in CLL cells; all primary cells in this study were sensitive to the growth-inhibitory effects of this cytokine [270].

Figure 7 TGF-β signaling in the bone marrow microenvironment of multiple myeloma. Myeloma cells are able to produce TGF-β cytokine which influence cells of bone marrow microenvironment such as osteoblast progenitors, bone marrow stromal cells. Moreover, it disrupts T cell proliferation and activation.
In Burkitt’s lymphoma, TGF-β-mediated growth arrest is associated with transcriptional repression of the E2F-1 gene. On the other hand, over-expression of the E2F-1 gene overcomes the TGF-β-mediated G1 arrest. So, the transcriptional repression of the E2F-1 gene is required for growth arrest suggesting that TGF-β can effectively exert tumor suppression also in cells without c-Myc, p15INK4B, and p21CIP1 regulation [271]. Inman and Allday reported that in Burkitt’s lymphoma, cells express normal levels of TβRI RNA and protein, but decreased levels of TβRII RNA, leading to lack of responsiveness to TGF-β1 [272].

**Multiple myeloma**

In multiple myeloma (MM), higher levels of TGF-β are secreted by myeloma cells as well as bone marrow stromal cells (BMSC). TGF-β secretion escalates with the stage of B cell differentiation (Figure 7). Increased production of TGF-β is followed by increased interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) secretion by BMSC, related to tumor cell proliferation. TGF-β is the major inducer of IL-6 and VEGF, two important cytokines of MM. On the other hand, TGF-β inhibits proliferation and Ig secretion of normal B cells [273].

After treatment with TβRI kinase inhibitor (SD-208), decreased production of IL-6 and VEGF and also attenuated tumor cell growth was observed. Mechanism of action of SD-208 is blocking nuclear accumulation of SMAD2/3 and related production of IL-6. This leads to inhibition of MM cell growth, survival, drug resistance and migration [274].

In MM, no mutations in TβRI or TβRII genes were described; MM cells contain TβRI and TβRII proteins in the cytoplasm. Resistance to the growth-inhibitory functions of TGF-β signaling develops, possibly due to defective trafficking of TβRI and TβRII to the cell surface in these cells [275,276]. Possibly, the loss of TβRII expression on the cell surface is the result of gene silencing by hypermethylation correlating to poor survival [277]. TβRII expression is diminished on mRNA and protein level in MM, enhancing cell growth, proliferation, mobility, heterotrophic cell–cell adhesion and contributing to disease progression [278].

Serum level of TGF-β is an important prognostic factor in MM. Higher levels of this cytokine mean lower levels of normal Ig resulting in immune impairment [279]. TGF-β secreted from MM cells disrupts proliferation, activation and IL-2 responsiveness in T cells. TGF-β is important in this immune-suppression, and its intensity of suppression is tumor burden dependent [280].

In MM patients, TGF-β represses bone formation in bone lesions. Initially, TGF-β enhances proliferation of osteoblast progenitors and promotes mineralization of bone matrix. Then, TGF-β inhibits subsequent phases of differentiation of osteoblasts and represses mineralization of matrix. This effect can be abrogated by inhibitors of TβRII kinase domain (reviewed in [281]).

**Conclusion**

TGF-β signaling is complex and finely regulated fundamental pathway, which has an important role during human development and adult life. It is broadly intertwined with other signaling pathways. Moreover, it is involved in cancerogenesis of solid tumors as well as hematological malignancies. Paradoxically, TGF-β is both a tumor suppressor and tumor promoter. The tumor suppressor activities are widely described as anti-proliferative and apoptotic effects. During cancer progression, tumor frequently avoids tumor suppressive activities of TGF-β either by acquiring mutations of signaling components or by inhibiting its anti-proliferative response. This ‘switch’ helps the tumor to use TGF-β as an oncogenic factor inducing tumor motility, invasion, metastasis and epithelial-to-mesenchymal transition. Advances in the study of molecular mechanisms that elucidate oncogenic activities of TGF-β lead to a strong desire to target TGF-β signaling in cancer therapy. However, the exact mechanisms involved in the malignant transformation of TGF-β needs to be clarified. Only then, it will be possible to develop successful therapeutic strategies as well as provide new therapeutic targets to restore the normal TGF-β function.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

L.K. wrote the original manuscript, L.S. and R.H. cooperated on revising the manuscript. S.S. revised the manuscript critically and approved the final version of the manuscript. All authors read and approved the final manuscript.

**Acknowledgments**

This work was supported by grant of The Ministry of Education, Youth and Sports: MSM0021622434 and grants of The Ministry of Health NT12130 and NT11154. The authors wish to thank John B. Smith for proofreading the manuscript.

Received: 23 May 2012 Accepted: 28 August 2012 Published: 3 September 2012

**References**

1. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144(5):646–674.
2. Tian M, Neil JR, Schiemann WP: Transforming growth factor-β and the hallmarks of cancer. Cell Signal 2011, 23:951–962.
3. Derynck R: The TGF-β Family: Cold Spring Harbor Laboratory; 2008. Press.
4. Sporn MB, Todaro GJ: Autocrine secretion and malignant transformation of cells. N Engl J Med 1980, 303:878–880.
5. de Larco JE, Todaro GJ: Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci USA 1978, 75:4001–4005.
6. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB: New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci USA 1981, 78:5339–5343.
26. Taipale J, Miyazono K, Heldin CH, Keski-Oja J: Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in collagenation in vitro. Proc Natl Acad Sci USA 1986, 83:4167–4171.
28. Flaumenhaft R, Abe M, Mignatti P, Rifkin DB: Transforming growth factor-beta binding protein. J Cell Biol 1984, 98:407–415.
29. Davis LA, Hinchcliff KL, Driver DS, Flexner P, Goeddel DV: TGF-beta binding protein associates to fibroblast extracellular matrix via latent growth factorbeta binding protein-1 that mediates bonding to the weight complex of transforming growth factor beta 1. J Biol Chem 1995, 270:138–148.
51. Sun PD, Davies DR: The cytokine-knot growth-factor superfamily. Annu Rev Biophys Biomol Struct 1995, 24:269–291.

52. Shi Y, Massague J: Mechanisms of TGF-[beta] Signaling from Cell Membrane to the Nucleus. Cell 2003, 113:685–700.

53. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J: Mechanism of activation of the TGF-[beta]-receptor. Nature 1994, 370:341–347.

54. Derynck R, Feng X-H: TGF-[beta] receptor signaling. Biochimica et Biophysica Acta (BBA) Reviews on Cancer 1997, 1333:F105–F150.

55. Finnson KW, Parker WL, Chi Y, Hoemann CD, Goldring BM, Antoniou J, Philip A: Endoglin differentially regulates TGF-[beta]-induced Smad2/3 and Smad1/5 signaling and its expression correlates with extracellular matrix production and cellular differentiation state in human chondrocytes. Osteoarthr Cartil 2010, 18:1518–1527.

56. Kerscher O, Felberbaum R, Hochstrasser M: Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 2006, 22:159–180.

57. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL: Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-[beta] receptor for degradation. Mol Cell 2000, 6:1365–1375.

58. Elbasiou T, Mushiki M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K: Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001, 276:12477–12480.

59. Kang JS, Saunier EF, Akhurst RJ, Derynck R: The type I TGF-[beta]-receptor is covalently modified and regulated by sumoylation. Nat Cell Biol 2008, 10:654–664.

60. Chen YG: Endocytosis regulation of TGF-[beta] signaling. Cell Res 2009, 19:58–70.

61. Attisano L, Wrana JL: Smads as transcriptional co-modulators. Curr Opin Cell Biol 2000, 12:235–243.

62. Liu F, Hata A, Baker JC, Doody J, Cárcamo J, Harland RM, Massagué J: A human Mad protein acting as a BMP-regulated transcriptional activator. Nature 1996, 381:620–623.

63. Massagué J, Seoane J, Wotton D: Smad transcription factors. Genes & Development 2005, 19:2783–2810.

64. Hayashi H, Abdollahi S, Qiu Y, Cai J, Xu Y-Y, Grinnell BW, Richardson MA, Topper JN, Gimbrone MA Jr, Wrana JL, Falb D: The MAD-related protein smad7 associates with the TGF[beta] receptor and functions as an antagonist of TGF[beta] signaling. Cell 1997, 89:1165–1173.

65. Hata A, Lagna G, Massagué J: Hemmati-Brivanlou A: Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 1998, 12:1869–1876.

66. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL: SARA, a FYVE domain Protein that recruits Smad2 to the TGF-[beta] Receptor. Cell 1998, 99:779–791.

67. Watanabe Y, Itoh S, Goto T, Ohsiri E, Inamitsu K, Itoh F, Satoh K, Imafuku T, Miyazono K: Crystal structure of a phosphorylated Smad2. J Biol Chem 2001, 276:12477–12480.

68. Liu F, Hata A, Baker JC, Doody J, Cárcamo J, Harland RM, Massagué J: A human Mad protein acting as a BMP-regulated transcriptional activator. Nature 1996, 381:620–623.

69. Hata A, Lagna G, Massagué J, Hemmati-Brivanlou A: Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 1998, 12:1869–1876.

70. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL: SARA, a FYVE domain Protein that recruits Smad2 to the TGF[beta] Receptor. Cell 1998, 99:779–791.

71. Xu L, Kang Y, Massagué J: Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci USA 2001, 98:992–999.

72. Chi CR, Kang Y, Massagué J: Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci USA 2001, 98:992–999.
98. Amendt C, Schirmacher P, Weber H, Blessing M: Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 1998, 17:25–34.

99. Wang XJ, Lieber KM, Tsai S, O’Malley BW, Roop DR: Development of gene-switch transgenic mice that inducibly express transforming growth factor-beta1 in the epidermis. Proc Natl Acad Sci USA 1999, 96:8483–8488.

100. Weeks BH, He W, Olson KL, Wang XJ: Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis. Cancer Res 2001, 61:7433–7443.

101. Hannon GJ, Beach D: p53INK4B is a potential effector of TGF-[beta]-induced cell cycle arrest. Nature 1994, 371:257–261.

102. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang YF: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995, 92:5549–5554.

103. Poljak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A: Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A: Alterations in components of the TGF-beta superfamily in carcinoma incidence and an acceleration of carcinoma development. J Biol Chem 2005, 280:1331–1337.

104. Alterations in components of the TGF-beta superfamily destabilizes cdc25C and promotes glioma cell invasion. J Neurosurg 1998, 88:529–534.

105. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501–1512.

106. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501–1512.

107. Reindlottir I, Massague J: The subcellular loci of p15(INK4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 1997, 11:492–503.

108. Sandhu C, Garbe J, Bhattacharya N, Daksis J, Pan CH, Yaswen P, Koh J, Slingerland JM, Stampfer MP: Transforming growth factor beta stabilizes p15INK4b protein, increases p15INK4b-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol Cell Biol 1997, 17:2458–2467.

109. Iavarone A, Massague J: E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocytes cell cycle arrest. Mol Cell Biol 1999, 19:916–922.

110. Chen CR, Kang Y, Siegel PM, Massague J: E2F4/S and p107 as smad cofactors linking the TGF[beta] Receptor to c-myc Repression. Cell 2002, 110:19–32.

111. Levy L, Hill CL: Alterations in components of the TGF-beta superfamily signalling pathways in human cancer. Cytokine Growth Factor Rev 2008, 19:141–158.

112. Teicher BA: Malignant cells, directors of the malignant process: role of transforming growth factor-beta1 in malignant glioma cells with functional receptors. J Neurosurg 1998, 88:529–534.

113. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501–1512.

114. Reindlottir I, Massague J: The subcellular loci of p15(INK4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 1997, 11:492–503.

115. Sandhu C, Garbe J, Bhattacharya N, Daksis J, Pan CH, Yaswen P, Koh J, Slingerland JM, Stampfer MP: Transforming growth factor beta stabilizes p15INK4b protein, increases p15INK4b-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol Cell Biol 1997, 17:2458–2467.

116. Iavarone A, Massague J: E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocytes cell cycle arrest. Mol Cell Biol 1999, 19:916–922.

117. Chen CR, Kang Y, Siegel PM, Massague J: E2F4/S and p107 as smad cofactors linking the TGF(beta) Receptor to c-myc Repression. Cell 2002, 110:19–32.

118. Levy L, Hill CL: Alterations in components of the TGF-beta superfamily signalling pathways in human cancer. Cytokine Growth Factor Rev 2008, 19:141–158.

119. Teicher BA: Malignant cells, directors of the malignant process: role of transforming growth factor-beta1 in malignant glioma cells with functional receptors. J Neurosurg 1998, 88:529–534.

120. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501–1512.

121. Reindlottir I, Massague J: The subcellular loci of p15(INK4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 1997, 11:492–503.

122. Sandhu C, Garbe J, Bhattacharya N, Daksis J, Pan CH, Yaswen P, Koh J, Slingerland JM, Stampfer MP: Transforming growth factor beta stabilizes p15INK4b protein, increases p15INK4b-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol Cell Biol 1997, 17:2458–2467.

123. Iavarone A, Massague J: E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocytes cell cycle arrest. Mol Cell Biol 1999, 19:916–922.

124. Chen CR, Kang Y, Siegel PM, Massague J: E2F4/S and p107 as smad cofactors linking the TGF(beta) Receptor to c-myc Repression. Cell 2002, 110:19–32.

125. Levy L, Hill CL: Alterations in components of the TGF-beta superfamily signalling pathways in human cancer. Cytokine Growth Factor Rev 2008, 19:141–158.

126. Teicher BA: Malignant cells, directors of the malignant process: role of transforming growth factor-beta1 in malignant glioma cells with functional receptors. J Neurosurg 1998, 88:529–534.

127. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501–1512.

128. Reindlottir I, Massague J: The subcellular loci of p15(INK4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 1997, 11:492–503.

129. Sandhu C, Garbe J, Bhattacharya N, Daksis J, Pan CH, Yaswen P, Koh J, Slingerland JM, Stampfer MP: Transforming growth factor beta stabilizes p15INK4b protein, increases p15INK4b-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol Cell Biol 1997, 17:2458–2467.

130. Iavarone A, Massague J: E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocytes cell cycle arrest. Mol Cell Biol 1999, 19:916–922.

131. Chen CR, Kang Y, Siegel PM, Massague J: E2F4/S and p107 as smad cofactors linking the TGF(beta) Receptor to c-myc Repression. Cell 2002, 110:19–32.

132. Levy L, Hill CL: Alterations in components of the TGF-beta superfamily signalling pathways in human cancer. Cytokine Growth Factor Rev 2008, 19:141–158.

133. Teicher BA: Malignant cells, directors of the malignant process: role of transforming growth factor-beta1 in malignant glioma cells with functional receptors. J Neurosurg 1998, 88:529–534.
139. Korpal M, Kang Y: Targeting the transforming growth factor-beta signalling pathway in metastatic cancer. Eur J Cancer 2010, 46:1232–1240.

140. Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG: TGF-beta signalling in colon carcinogenesis. Cancer Lett 2012, 314:1–7.

141. Fakhrai H, Wamstl JC, Liu L, Nicholson GL, Murphy-Satter CS, Ruppert J, Shavler CL: Phase I clinical trial of a TGF-beta-antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther 2006, 13:1035–1060.

142. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Fakhrai H, Mantil JC, Liu L, Nicholson GL, Murphy-Satter CS, Ruppert J, Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Udagawa Y: Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin. Oncol Rep 2011, 25:131–138.

143. Antoiny ML, Nair R, Sebastian P, Karunagaran D: Changes in expression, and/or mutations in TGF-β receptors (TGF-βRI and TGF-βRII) and Smad 4 in human ovarian tumors. J Cancer Res Clin Oncol 2009, 135:351–361.

144. Jachimczak P, Hawdeh B, Bollari C, Collignon B, Pemberton G, Graff JR, Carter JH: Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res 2001, 61:4669–4682.

145. Kaklamani VG, Hou N, Biam Y, Reich J, Ott K, Michel LS, Rubinstein WS, Todemaker A, Parbe K: TGFβRI6α and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol. Official Journal of the Am J Clin Oncol 2003, 21:3236–3243.

146. Biswas S, Trbobić P, Romero-Gallo J, Billheimer DL, Williams J, Markowitz SD, Grady WM: Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells. Genes Chromosomes Cancer 2008, 47:95–106.

147. Schutte M, Hruban RH, Hadrick L, Cho K, Nandasary GM, Weinstein CL, Bova GS, Isaac WB, Cairns P, Nawroz H, et al: DPC4 Gene in Various Tumor Types. Cancer Res 1996, 56:2527–2530.

148. Do T-V, Kubo A, Ha D, Sturgis CD, Woodford TK: Transforming growth Factor-B1, transforming growth factor-β2, and transforming growth factor-β3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol Cancer Res 2008, 6:695–705.

149. Chan MWY, Huang Y-W, Hartman-Frey C, Kuo C-T, Deatherage D, Qin H, Cheng ASL, Yan PS, Davuluri RV, Huang TH, Jin VX: CHI-Pseq Defined Genome-Wide Map of TGFβ/SMAD4 Targets: Implications with Clinical Outcome of Ovarian Cancer. PLoS One 2011, 6(6):2606.

150. Wistrom P, Stattin P, Franck-Lisztrabj J, Damber JF, Bergh A: Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998, 37:19–29.

151. Yu N, Kozlowski JM, Park II, Chen L, Zhang Q, Xu D, Doll JA, Crawford SE, Yu N, Kozlowski JM, Park II, Chen L, Zhang Q, Xu D, Doll JA, Crawford SE, Jin VX: CHI-Pseq Defined Genome-Wide Map of TGFβ/SMAD4 Targets: Implications with Clinical Outcome of Ovarian Cancer. PLoS One 2011, 6(6):2606.

152. Kulpke A, Statnick P, Frank-Lisztrabj J, Damber JF, Bergh A: Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998, 37:19–29.

153. Yu N, Kozlowski JM, Park II, Chen L, Zhang Q, Xu D, Doll JA, Crawford SE, Jin VX: CHI-Pseq Defined Genome-Wide Map of TGFβ/SMAD4 Targets: Implications with Clinical Outcome of Ovarian Cancer. PLoS One 2011, 6(6):2606.

154. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008, 34:193–205.

155. Jølund J, Bøstrøm AK, Lindgren D, Manns S, Mou斯塔kas A, Ljunghberg B, Johansson M, Fredlund E, Axelsson H: The Notch and TGF-β Signaling Pathways Contribute to the Aggressiveness of Clear Cell Renal Cell Carcinoma. PLoS One 2011, 6(2):e19297.

156. Shavler CL, Wang H, Kingsley EA, Riberipper GP, Russell P: Molecular profiling of bladder cancer: Involvement of the TGF-β1 pathway in bladder cancer progression. Cancer Lett 2008, 265:27–38.

157. Li Y, Yang K, Mao Q, Zheng X, Kong D, Xie L: Inhibition of TGF-β receptor I by siRNA suppresses the motility and invasiveness of T24 bladder cancer cells via modulation of integrins and matrix metalloproteinase. Int Urol Nephrol 2009, 42:315–323.
176. Zhang Q, Rubenstein JN, Jiang TL, Pims M, Javonovic B, Yang X, Kim S-J, Park I, Lee C: Insensitivity to transforming growth factor-beta results from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP), Mol Endocrinol 2005, 19:2300–2399.

177. Lati A, Pesche S, Valier A, Fournier G, Cussenot O, Linderer R: Expression and mutational analysis of the MADR2/smad2 gene in human prostate cancer. Prostate 1999, 40:2225–231.

178. Yin Z, Babaian RJ, Troncoso P, Strom SS, Spitz MR, Caudell JJ, Stein JD, Kubiczkova

179. Hahm KB, Lee KM, Kim YB, Hong WS, Lee WH, Han SU, Kim MW, Ahn BO, Oh TY, Lee MH, et al: Conditional loss of TGF-beta signalling leads to increased susceptibility to gastrointestinal carcinogenesis in mice. Aliment Pharmacol Ther 2002, 16(Suppl):2115–127.

180. Fu H, Hu Z, Wen J, Wang K, Liu Y: TGF-beta promotes invasion and metastasis of gastric cancer cells by increasing Fas1 expression via ERK and JNK signal pathways. Acta Biochim Biophys Sin (Shanghai) 2009, 41:458–566.

181. Shintro Q, Yashiro M, Toyokawa T, Nishii T, Kaizaki R, Matsuoka T, Noda S, Kubo N, Tanaka H, Doi Y, et al: Phosphorylated smad2 in advanced stage gastric carcinoma. BMC Cancer 2010, 10:552.

182. Han SU, Kim HT, Seong DH, Kim YS, Park YS, Bang YJ, Yang HK, Kim SJ: Loss of the Smad3 expression increases susceptibility to tumorigenesis in human gastric cancer. Oncogene 2004, 23:1333–1341.

183. Yoo YA, Kang BH, Kim JS, Oh SC: Sonic hedgehog signalling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the AK5- Smad 3 pathway. Carcinogenesis 2008, 29:490–496.

184. Mamiya T, Yamazaki K, Masugi Y, Mori T, Effenri K, Du W, Bibi T, Tanabe M, Ueda M, Takayama T, Sakamoto M. Reduced transforming growth factor-beta receptor II expression in hepatocellular carcinoma correlates with intrapathic metastasis. Lab Invest 2010, 90:1339–1345.

185. Longerich T, Brehahn K, Odenthal M, Petmecky K, Schlimme C. Factors of transforming growth factor beta signalling are co-regulated in human hepatocellular carcinoma. Virchows Arch 2004, 445:389–396.

186. Yakicić MR, Irmak MB, Romano M, Kew M, Oztürk M: Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 1999, 18:4879–4883.

187. Yang YA, Zhang GM, Feigenbaum L, Zhang YE: Smad3 reduces susceptibility to hepatocarcinogenesis by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell 2006, 9:445–457.

188. Yamamura Y, Hua X, Bergelson S, Lodish HF: Critical Role of Smads and AP-1 complex in transforming growth factor-β-dependent Apoptosis. J Biol Chem 2000, 275:36295–36302.

189. Mazzaocca A, Fransvea E, Lavezzi G, Antonaci S, Giannelli G: Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 2009, 50:1490–1511.

190. Mazzaocca A, Fransvea E, Dituri F, Lupo L, Antonaci S, Giannelli G: Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 2010, 51:523–534.

191. Flechsig P, Dadrich M, Bickelhaupt S, Jenne J, Hausker K, Timcke P, Peschke P, Hahn EW, Gröne HJ, Yingling L, et al: V1209761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals. Clin Cancer Res 2011, 17:3616–3627.

192. Friedman E, Gold LI, Klimenta D, Zeng ZS, Winawer S, Cohen AH: High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev: A Publication of the American Association for Cancer Research, Co-sponsored by the American Society of Preventive Oncology 1995, 4:549–554.

193. Yan Z, Winawer S, Friedman E: Two different signal transduction pathways can be activated by transforming growth factor beta 1 in epithelial cells. J Biol Chem 1994, 269:13231–13237.

194. Eppert K, Scherer SW, Oszczek E, Hrone R, Hoodless P, Kim H, Tsui L-C, Bapat B, Callinger S, Andruslis I, et al: MADR2 Maps to 18q21 and Encodes a TGF-β(β)-Regulated Protein That Is Functionally Mutated in Colorectal Carcinoma. Cell 1994, 76:364–371.

195. Ku JJ, Park SH, Yoon KA, Shin YK, Kim KH, Choi JS, Kang HC, Kim JH, Han IO, Park JG: Genetic alterations of the TGF-beta signaling pathway in colorectal cancer cell lines: a novel mutation in Smad3 associated with the inactivation of TGF-beta-induced transcriptional activation. Cancer Lett 2007, 247:283–292.

196. Ando T, Sugai T, Habano W, Jiao Y-F, Suzuki K: Analysis of SMAD4/DPC4 gene alterations in multiploid colorectal carcinomas. J Gastroenterol 2005, 40:708–715.

197. Takagi Y, Kohmura H, Futamura M, Kida H, Tanemura H, Shimokawa K, Saji S: Somatic alterations of the DPC4 gene in human colorectal cancers. Colorectal Carcinoma. 2006, 86:543–552.

198. Eppert K, Scherer SW, Oszczek E, Hrone R, Hoodless P, Kim H, Tsui L-C, Bapat B, Callinger S, Andruslis I, et al: MADR2 Maps to 18q21 and Encodes a TGF-β-Regulated Protein That Is Functionally Mutated in Colorectal Carcinoma. Cell 1994, 76:364–371.

199. Ku JJ, Park SH, Yoon KA, Shin YK, Kim KH, Choi JS, Kang HC, Kim JH, Han IO, Park JG: Genetic alterations of the TGF-beta signaling pathway in colorectal cancer cell lines: a novel mutation in Smad3 associated with the inactivation of TGF-beta-induced transcriptional activation. Cancer Lett 2007, 247:283–292.
response in human colon carcinoma cells in a Smad4/DPC4 independent manner. Cancer Lett 2008, 264:281–287.

215. Ali NA, McKay MJ, Molloy MP: Proteomics of Smad4 regulated transforming growth factor-beta signalling in colon cancer cells. Mol Biol Easton 2010, 6:2322–2332.

216. Nikolic A, Markovic S, Knezevic S, Knicakopic Z, Ristanovic M, Radijokovic D: Structural and functional analysis of SMAD4 gene promoter in malignant pancreatic and colorectal tissues: Detection of two novel polymorphic nucleotide repeats. Cancer Epidemiol Biomarkers 2011, 35:265–271.

217. Markowitz S, Wang J, Myeroff L, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kizirl K, Vogelstein B: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (New York, NY) 1995, 268:1336–1338.

218. Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kizirl K, Vogelstein B: Microsatellite Instability and Mutations of the Transforming Growth Factor β Type II Receptor Gene in Colorectal Cancer. Cancer Res 1995, 55:5548–5550.

219. Grady WM, Myeroff LL, Swinkler SE, Rajput A, Sadim M, Kaklamani V, Pennison MJ, Zeng Q, Bellamy A, et al: Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 1999, 59:320–324.

220. Liu XQ, Rajput A, Geng L, Ongchin M, Chaudhuri A, Wang J: Identification of two novel polymorphic nucleotide repeats. Cancer Epidemiol Biomarkers 2011, 35:265–271.

221. Pasche B, Wisinski KB, Sadim M, Kaklamani V, Pennison MJ, Zeng Q, Bellamy A, et al: Constitutively decreased TGFβRIII allelic expression is a common finding in colorectal cancer and is associated with three TGFβRII SNPs. J Exp Clin Cancer Res 2010, 29:57–57.

222. Gatze CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, Datto MB, Blobe GC: Type III TGF-β Receptor Enhances Colon Cancer Cell Migration and Anchorage-independent Growth. Neoplasia 2011, 13:758–770.

223. Tian X, Du H, Fu X, Li K, Li A, Zhang Y: Loss of TβRII expression in human colon cancer cells. Biochem Biophys Res Commun 2009, 380:478–483.

224. Cottonham CL, Kanoek S, Xu L: mir-21 and mir-31 Converge on TIM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem 2010, 285:32923–32932.

225. Furukawa T: Molecular pathology of pancreatic cancer: implications for molecular targeting therapy. Clin Gastroenterol H: Clin Pract J Am Gastroen Assoc 2009, 75:35–59.

226. Fujisawa H, Reis RM, Nakamura M, Collela S, Yonekawa Y, Kleihues P, Ohgaki H: Loss of heterozygosity on chromosome 10 is more extensive in primary (De Novo) than in secondary glioblastomas. Lab Invest 2000, 80:65–72.

227. Hahn SA, Shamsul Hoque ATM, Parsons R, Moskaluk CA, da Costa LT, Schutte M, Cottonham CL, Kaneko S, Xu L: Defective expression of transforming growth factor β Receptor Type II is associated with CpG methylated promoter in primary non-small cell lung cancer. Clin Cancer Res 2004, 10:2539–2546.

228. Jiang X, Liu R, Lei Z, You J, Zhou Q, Zhang H: [Defective expression of TGFβ3 gene and its molecular mechanisms in non-small cell lung cancer cells]. Zhongguo Fei Ai Za Zhi 2010, 13:451–457.

229. Pasche B, Kolachana P, Nafa K, Satagopan J, Chen YG, Lo RS, Brener D, Yang JA, et al: Mutations of the Smad4 gene in colorectal cancers: Detection of two novel polymorphic nucleotide repeats. Cancer Epidemiol Biomarkers 2011, 20:2581–2587.

230. Jonle S, Dracheva T, Yang S-H, Meerzaman D, Fukuoka J, Shakoori A, Shilo K, Travis WD, Jen J: SMAD4 contributes to patient survival in non-small cell lung cancer and its knockdown reestablishes TGF-beta homeostasis in lung cancer cells. Cancer Res 2008, 68:9686–9692.

231. Xu CC, Wu LM, Sun W, Zhang N, Chen W-S, Fu X-N: Effects of TGF-β signaling blockade on human A549 lung adenocarcinoma cells lines. Molecular Medicine Reports 2011, 4:1007–1015.

232. Hu X, Gid D, Moscinski LC, Zhang X, Macachero V, Zuckerman KS: TGFβ regulates the expression and activities of G2 checkpoint kinases in human myeloid leukemia cells. Cytokine 2007, 37:155–162.

233. Jakubowiak A, Pouponnot C, Berguido F, Frank R, Mao S, Massague J, Nimer SD: Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J Biol Chem 2000, 275:40282–40287.

234. Imai Y, Kurokawa M, Iizuka K, H rampi K, Maki K, Ogawa S, Chiba S, Mitani K, Hirai K: Mutations of the Smad4 gene in acute myelogenous leukemia and their functional implications in leukaemogenesis. Oncogene 2001, 20:2886–96.

235. Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H: The (3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells. Blood 1998, 92:4003–4012.

236. Jones L, Wei G, Sevcikova S, Phan V, Jain S, Shieh A, Wong JC, Li M, Dubinsky J, Maunakea ML, et al: Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. J Exp Med 2010, 207:2581–2594.

237. Lin HK, Bergmann S, Pandolff P: Cytoplasmic PML function in TGF-beta signalling. Nature 2004, 431:205–211.

238. Ernst T, La Rosée P, Müller MC, Hochhaus A: BCR-ABL mutations in chronic myeloid leukemia. Hematol Oncol Clin North Am 2011, 25:997–1008. v-vi.

239. Alt F, Abecassis L, Bourgeade MF: Bcr-Abl activates the AKT/Fox O3 signalling pathway to restrict transforming growth factor-beta-mediated cytostatic signals. EMBO Rep 2005, 6:895–991.

240. Januleit T, van der Kuip H, Miething C, Michels H, Hallek M, Duyster J, Luiten WC: Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood 2000, 96:1933–1939.

241. Ogawa S, Kurokawa M, Tanaka T, Tanaka K, H angiashi A, Mitani K, Kami noda N, Yazaki Y, Hirai H: Increased Evi-1 expression is frequently observed in blastic chronic myelocytic leukemia. Leukemia 1996, 10:788–794.

242. Kurokawa M, Mitani K, Irie K, Matsu moto K, Hirai H: The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 1998, 394:92–96.

243. Maller GA, Frost V, Melo JV, Chariot A: Upregulation of the TGFβeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia. FEBS Lett 2007, 581:1329–1334.

244. Wolffram LF, Fernandez TM, Mamura M, Fuller W, Kumar R, Cole DE, Byfield S, Felici A, Panderds KC, Waltz TM, et al: Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med 2004, 351:552–559.

245. Ford AM, Palmi C, Bueno C, Hong D, Cardus P, Dizard D, Cazzaniga G, Enver T, Graves M: The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest 2011, 119:836–836.

246. Scott SA, Kinnata T, Dong WF, Ichinoshamasra R, Bergen S, Kerviche A, Sheridan D, DeCoteau JF: Methylation status of cyclin-dependent kinase inhibitor genes within the transforming growth factor beta pathway in human T-cell lymphoblastic lymphoma/leukaemia. Leuk Res 2004, 28:1293–1301.

247. Mori N, Morishita M, Tsukazaki T, Giam CZ, Kumatori A, Tanaka Y, Yamamoto N: Human T-cell leukemia virus type 1 oncoprotein Tax represses Smad-dependent transforming growth factor beta signaling through
interaction with CREB-binding protein/p300. Blood 2001, 97:2137–2144.

254. Lee DK, Kim BC, Brady JN, Jeang KT, Kim SJ: Human T-cell lymphotropic virus type 1 tax inhibits transforming growth factor-beta signaling by blocking the association of Smad proteins with Smad-binding element. J Biol Chem 2002, 277:53766–53775.

255. Aernou B, Villemin A, Nicot C, Mordelet E, Charneau P, Kersaux J, Zermati Y, Maunivel A, Barzabachi A, Hermine O: Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. Blood 2002, 99:2493–2500.

256. Shehata M, Schwarzeimier JD, Hilgarth M, Hubmann R, Duechler M, Kadin ME, Cavaille-Coll MW, Gertz R, Massagué J, Cheifetz S, George D: Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci USA 1994, 91:6002–6006.

257. Kraus PL, Lindemann D, DeCoteau JF, Perlman R, Yankelev H, Hille M, Kadin ME, Lodish HF: A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol Cell Biol 1996, 16:3480–3489.

258. Schiernann WP, Pfeiffer WM, Levi E, Kadin ME, Lodish HF: A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood 1999, 94:2834–2841.

259. Nakahata S, Yamazaki S, Nakauchi H, Morishita K: Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGFBeta1-mediated growth suppression in adult T-cell leukemia/lymphoma. Oncogene 2010, 29:4157–4169.

260. Munoz O, Fend F, de Beaumont R, Husson H, Astier A, Freedman AS: TGFBeta-mediated activation of Smad1 in B-cell non-Hodgkin’s lymphoma and effect on cell proliferation. Leukemia 2004, 18(15):2015–2025.

261. Bakkeba M, Huse K, Hilden VI, Smeland EB, Oskvold MP: TGFBeta-induced growth inhibition in B-cell lymphoma correlates with Smad1/S signalling and constitutively active p38 MAPK. BMC Immunol 2010, 11:57.

262. Chen G, Ghosh P, Osawa H, Sasaki CY, Rezanka L, Yang J, O’Farrell TJ, Longo DL: Resistance to TGFBeta1 correlates with aberrant expression of TGFBeta2 receptor II in human B-cell lymphoma cell lines. Blood 2007, 109:5301–5307.

263. Rai D, Kim SW, Mckeller MR, Dahia PL, Aguari RC: Targeting of SMADS links microRNA-155 to the TGFBeta pathway and lymphomagenesis. Proc Natl Acad Sci USA 2010, 107:3111–3116.

264. Douglas RS, Capocasale RJ, Lamb RJ, Nowell PC, Moore JS: Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor beta. Blood 1997, 89:941–947.

265. Laganeux L, Delforge A, Bron D, Massy M, Bernier M, Stryckmans P: Heterogenous response of B lymphocytes to transforming growth factor-beta in B-cell chronic lymphocytic leukaemia: correlation with the expression of TGFBeta receptors. Br J Haematol 1997, 97:612–620.

266. DeCoteau JF, Kraus PL, Yankelev H, Reis MD, Lowsky R, Lodish HF, Kadin ME: Loss of functional cell surface transforming growth factor beta (TGFBeta) type I receptor correlates with insensitivity to TGFBeta in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1997, 94:5877–5881.

267. Schiernann WP, Potzer D, Pfeiffer WM, Levi E, Rai KR, Kraus P, Kadin ME: Transforming growth factor-beta (TGFBeta)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGFBeta receptor. Cancer Detect Prev 2004, 28:57–64.

268. Jellink DF, Tschumper RC, Stolovitzky GA, Iturria SI, Tu Y, Lepre J, Shah N, Kay NE: Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res 2003, 1:346–361.

269. Lotz M, Ranheim E, Kipps TJ: Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 1994, 179:999–1004.

270. Spender LC, Inman DJ: TGFBeta induces growth arrest in Burkitt lymphoma cells via transcriptional repression of EZF-1. J Biol Chem 2009, 284:1435–1442.

271. Inman DJ, Alliday MJ: Resistance to TGFBeta1 correlates with a reduction of TGFBeta type II receptor expression in Burkitt’s lymphoma and Epstein-Barr virus transformed B lymphoblastoid cell lines. J Gen Virol 2000, 81:1567–1578.

272. Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidasie MB, Dedera DA, Schlossman RL, Anderson KC: Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 1996, 87:1928–1938.

273. Hayashi T, Hideshima T, Nguyen AN, Munoz O, Podar K, Hamsaki M, Ishituska K, Iayu H, Richardson P, Chakavarty S, et al: Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 2004, 10:7540–7546.

274. Amoroso SR, Huang N, Roberts AB, Potter M, Letterio JJ: Consistent loss of functional transforming growth factor beta receptor expression in murine plasmacytomas. Proc Natl Acad Sci USA 1998, 95:189–194.

275. Fernandez T, Amoroso S, Sharpe S, Jones GM, Blikovski V, Kovalchuk A, Wakefield LM, Kim SJ, Potter M, Letterio JJ: Disruption of transforming growth factor beta signaling by a novel ligand-dependent mechanism. J Exp Med 2002, 195:1247–1255.

276. de Carvalho F, Colleoni GW, Almeida MS, Carvalho AL, Vetteiro AL: TGFBetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int J Cancer 2009, 125:1985–1991.

277. Lambert KE, Huang H, Mythreye K, Blobe GC: The type III transforming growth factor-beta receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Mol Biol Cell 2011, 22:463–472.

278. Ryttovson MC, Repa C, Dedosissis GV, Mouzaki A, Simeonidis A, Stamatiou M, Manatis A: Serum transforming growth factor-beta 1 is related to the degree of immunoparesis in patients with multiple myeloma. Med Oncol 1998, 15:124–128.

279. Cook G, Campbell JD, Carr CE, Boyd KS, Franklin IM: Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J Leukoc Biol 1999, 66:981–988.

280. Matsumoto T, Abe M: TGFBeta-related mechanisms of bone destruction in multiple myeloma. Bone 2011, 48:129–134.